Screening for Malignancy After Augmentation Cystoplasty in Children With Spina Bifida: A Decision Analysis

Department of Urology, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA.
The Journal of urology (Impact Factor: 3.75). 08/2011; 186(4):1437-43. DOI: 10.1016/j.juro.2011.05.065
Source: PubMed

ABSTRACT Augmentation cystoplasty is the mainstay of surgical treatment for medically refractory neurogenic bladder in patients with spina bifida. Concerns regarding an increased risk of malignancy have prompted many centers to consider routine postoperative screening. We examine the potential cost-effectiveness of such screening.
A Markov model was used to compare 2 screening strategies among patients with spina bifida after cystoplasty, namely annual screening cystoscopy and cytology and usual care. Model parameters were informed via a systematic review of post-augmentation malignancy and cost estimates from published reports or government sources.
In a hypothetical cohort the individual increase in life expectancy for the entire cohort was 2.3 months with an average lifetime cost of $55,200 per capita, for an incremental cost-effectiveness ratio of $273,718 per life-year gained. One-way and two-way sensitivity analyses suggest the screening strategy could be cost effective if the annual rate of cancer development were more than 0.26% (12.8% lifetime risk) or there were a greater than 50% increase in screening effectiveness and cancer risk after augmentation. After adjusting for multiple levels of uncertainty the screening strategy had only an 11% chance of being cost effective at a $100,000 per life-year threshold or a less than 3% chance of being cost effective at $100,000 per quality adjusted life-year.
Annual screening for malignancy among patients with spina bifida with cystoplasty using cystoscopy and cytology is unlikely to be cost effective at commonly accepted willingness to pay thresholds. This conclusion is sensitive to a higher than expected risk of malignancy and to highly optimistic estimates of screening effectiveness.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Neurogenic bladder in the pediatric population underwent an evolution in treatment patterns during the 20th century. This paradigm change began with an evolving understanding of the health risks children with this condition face and the variable pathophysiology resulting in their condition. Introduction of clean intermittent catheterization and anticholinergic medication revolutionized care of these young patients. Advances in our knowledge of bladder pathology, and novel techniques to improve lower urinary tract function have made a variety of treatments available to patients. Although some similarities exist between adult and pediatric neurogenic bladder, the pediatric patient provides unique challenges with growth and development and helping children gain independence. Presented is a review of the treatment options and an algorithm to support the two main goals of treatment: protection of the upper urinary tract from renal function deterioration and development of social continence.
    Current Bladder Dysfunction Reports 06/2012; 7(2). DOI:10.1007/s11884-012-0131-1
  • [Show abstract] [Hide abstract]
    ABSTRACT: The surgical management of pediatric urinary incontinence secondary to neurogenic bladder and congenital anomalies is challenging, and continues to evolve with new surgical innovations. The goal of these surgical procedures is to achieve complete and socially acceptable urinary dryness, while preserving volitional voiding where possible, without causing damage to the upper tracts. This review focuses on recent studies and highlights the pros and cons of these advances, based on our experience. The short-term success in achieving urinary continence has to be tempered with the long-term implications of these reconstructive procedures, about which our knowledge is limited.
    Current Urology Reports 07/2013; DOI:10.1007/s11934-013-0333-x
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: CONTEXT: Bladder cancer (BCa) is the fourth most common cancer in men. Survival from the disease has not improved in the last 25 yr. Population-based screening theoretically provides the best opportunity to improve the outcomes of aggressive BCa. OBJECTIVE: To review the current literature regarding the usefulness and feasibility of screening for bladder cancer. EVIDENCE ACQUISITION: We conducted a nonsystematic review restricted to English using the keywords urinary bladder neoplasms, mass screening, mandatory testing, and early detection of cancer. We retrieved 184 articles and selected 22. EVIDENCE SYNTHESIS: There was no level 1 evidence (obtained from a randomised controlled trial [RCT]) addressing the impact of screening on BCa survival or tumour downstaging. No study assessed the diagnostic performance of urinary markers in the context of screening. Two case-control series suggested a benefit of screening on survival, and a third found a nonsignificant beneficial trend in favour of screening. Two studies suggested downstaging of BCa at diagnosis. Other reports concluded that most cancers detected with screening were of low grade and that current urinary testing cannot detect all tumours. Screening is likely to be of benefit in high-risk populations using cost-efficient high-performing urinary biomarkers. There was insufficient evidence to define an efficient screening protocol. CONCLUSIONS: Although BCa screening is theoretically feasible in a high-risk population, there is currently insufficient evidence to recommend it. This is due to insufficient data to define an efficient screening protocol with selection of an appropriate population and the lack of accurate and cost-effective urinary markers able to discriminate low-risk from high-risk cancers. Major improvements are needed in the evaluation of urinary biomarkers before evaluation in a RCT can be achieved.
    European Urology 01/2013; 63(6). DOI:10.1016/j.eururo.2012.12.062 · 10.48 Impact Factor